A phase II, double-blind, placebo-controlled, randomized clinical trial assessing toxicity and efficacy of MF101 for hot flashes and menopausal symptoms

Trial Profile

A phase II, double-blind, placebo-controlled, randomized clinical trial assessing toxicity and efficacy of MF101 for hot flashes and menopausal symptoms

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2012

At a glance

  • Drugs MF 101 (Primary)
  • Indications Hot flashes; Menopausal syndrome; Menopause
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CHIMES
  • Most Recent Events

    • 18 Jan 2012 Study acronym added
    • 18 Jan 2012 Results of a re-analysis published in Climacteric.
    • 12 Jun 2011 Results presented at the 13th World Congress on Menopause.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top